Micropapillary Carcinoma of Stomach: A Clinicopathologic and Immunohistochemical Study of 11 Cases

DSpace/Manakin Repository

Micropapillary Carcinoma of Stomach: A Clinicopathologic and Immunohistochemical Study of 11 Cases

Citable link to this page

 

 
Title: Micropapillary Carcinoma of Stomach: A Clinicopathologic and Immunohistochemical Study of 11 Cases
Author: Roh, Ji Hyeon; Srivastava, Amitabh; Lauwers, Gregory Y.; An, Jungsuk; Jang, Kee-Taek; Park, Cheol Keun; Sohn, Tae Sung; Kim, Sung; Kim, Kyoung-Mee

Note: Order does not necessarily reflect citation order of authors.

Citation: Roh, Ji Hyeon, Amitabh Srivastava, Gregory Y. Lauwers, Jungsuk An, Kee-Taek Jang, Cheol Keun Park, Tae Sung Sohn, Sung Kim, and Kyoung-Mee Kim. 2010. “Micropapillary Carcinoma of Stomach.” The American Journal of Surgical Pathology 34 (8) (August): 1139–1146. doi:10.1097/pas.0b013e3181e7043b.
Access Status: Full text of the requested work is not available in DASH at this time (“dark deposit”). For more information on dark deposits, see our FAQ.
Full Text & Related Files:
Abstract: Micropapillary carcinoma (MPC) of the stomach is a rare, newly recognized entity, and only 2 patients with this histology have been reported. We investigated clinicopathologic features, expression of mucin (MUC2, MUC5AC, MUC6, CD10) and cytokeratin profiles (CK7 and CK20), epidermal growth factor receptors (EGFR and HER2), prognostic markers (p53 and Ki-67), and outcomes in 11 MPCs of the stomach. The proportion of MPC component ranged from 5% to 70%. Micropapillary features were often found at the deep advancing edge of the tumor. Endolymphatic tumor emboli were found in 10 cases (91%) and lymph node metastases were found in 4 cases (36%). In MPCs, positive expression was observed for Ki-67 (82%), CK7 (73%), EGFR (64%), p53 (64%), MUC5AC (45%), MUC6 (36%), and CK20 (27%). However, MUC2, CD10, and HER2 expression was negative in all cases. In 9 conventional adenocarcinomas and 11 papillary adenocarcinomas with multiple endolymphatic tumor emboli, used as control, positive expression was observed for Ki-67 (100%), CK7 (90%), EGFR (80%), CK20 (70%), p53 (70%), MUC5AC (70%), MUC6 (60%), MUC2 (40%), CD10 (25%), and HER2 (15%). Expression of MUC2, CK20, and the Ki-67 labeling index was significantly higher in control adenocarcinomas as compared with MPCs (P<0.05). However, there was no significant difference in other clinicopathologic features and overall patient survival. Subclassification of MPCs into 2 subgroups according to the proportion of micropapillary component (cut-off value was 20%) failed to find any significant clinicopathologic differences (P>0.05). Although MPCs in other organs show a poor prognosis, this does not seem to be true for gastric MPCs. Further larger studies are necessary to confirm our initial findings.
Published Version: doi:10.1097/PAS.0b013e3181e7043b
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:35136068
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters